Gulf Coast Distillers is located in the East End. Courtesy of Gulf Coast Distillery

A Houston company is doing its part to help alleviate shortages of hand sanitizer that have been triggered by the coronavirus pandemic.

Gulf Coast Distillers has repurposed one of its production and bottling lines to produce the alcohol-based cleaning product.

C4U Hand Sanitizer could make its way into local retailers as early as later this week, the company announced. Exact locations and pricing will be announced once the product is ready for stores.

"As the coronavirus concerns have grown over the past week, and the supply of important health items has become sparse, we have decided to shift a significant part of our production resources to help our community in this time of need," Gulf Coast Distillers' president & CEO Carlos de Aldecoa said a statement.

For those unfamiliar, Gulf Coast operates a large distillery in Houston's East End. Some of its consumer brands include Giant Texas bourbon and BJ Hooker's vodka.

The company does not expect that switching one line over to hand sanitizer will significantly diminish the availability of those other products.

Producing hand sanitizer in response to recent shortages puts Gulf Coast in prestigious company. Luxury goods maker LVMH, a French firm that owns prestigious brands such as Louis Vuitton and Tiffany & Co., recently announced that it would also begin producing the product. Other distilleries across America have also begun to produce hand sanitizer to alleviate shortages.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.